Separation of influenza virus-like particles from baculovirus by polymer-grafted anion exchanger.
HIV-1 gag
anion exchange chromatography
downstream processing
insect cells
vaccines
Journal
Journal of separation science
ISSN: 1615-9314
Titre abrégé: J Sep Sci
Pays: Germany
ID NLM: 101088554
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
30
11
2019
revised:
17
02
2020
accepted:
11
03
2020
pubmed:
19
3
2020
medline:
4
2
2021
entrez:
19
3
2020
Statut:
ppublish
Résumé
The baculovirus expression vector system is a very powerful tool to produce virus-like particles and gene-therapy vectors, but the removal of coexpressed baculovirus has been a major barrier for wider industrial use. We used chimeric human immunodeficiency virus-1 (HIV-1) gag influenza-hemagglutin virus-like particles produced in Tnms42 insect cells using the baculovirus insect cell expression vector system as model virus-like particles. A fast and simple purification method for these virus-like particles with direct capture and purification within one chromatography step was developed. The insect cell culture supernatant was treated with endonuclease and filtered, before it was directly loaded onto a polymer-grafted anion exchanger and eluted by a linear salt gradient. A 4.3 log clearance of baculovirus from virus-like particles was achieved. The absence of the baculovirus capsid protein (vp39) in the product fraction was additionally shown by high performance liquid chromatography-mass spectrometry. When considering a vaccination dose of 10
Identifiants
pubmed: 32187844
doi: 10.1002/jssc.201901215
pmc: PMC7318652
doi:
Substances chimiques
Anions
0
Polymers
0
gag Gene Products, Human Immunodeficiency Virus
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2270-2278Subventions
Organisme : Austrian Science Fund FWF
ID : W 1224
Pays : Austria
Organisme : Austrian Science Fund
ID : FWF W1224
Organisme : Austrian Science Fund
ID : W1224
Organisme : Österreichische Forschungsförderungsgesellschaft
ID : 848951
Informations de copyright
© 2020 The Authors. Journal of Separation Science published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
Biologics. 2008 Mar;2(1):97-105
pubmed: 19707432
J Chromatogr A. 2016 Jul 15;1455:93-101
pubmed: 27286649
J Chromatogr A. 2017 Mar 3;1487:89-99
pubmed: 28110946
Expert Rev Vaccines. 2011 Nov;10(11):1569-83
pubmed: 22043956
Vaccine. 2013 Sep 13;31(40):4305-13
pubmed: 23891795
Anal Chem. 2014 Aug 5;86(15):7171-83
pubmed: 25047231
J Invertebr Pathol. 2016 Feb;134:15-22
pubmed: 26743500
J Chromatogr A. 2019 Mar 15;1588:77-84
pubmed: 30616980
Mol Biotechnol. 2010 Jul;45(3):226-34
pubmed: 20300881
Biotechnol Prog. 2005 Jan-Feb;21(1):154-60
pubmed: 15903253
J Virol. 2004 Jan;78(1):124-35
pubmed: 14671094
Trends Mol Med. 2010 Jul;16(7):313-20
pubmed: 20570562
J Virol. 1976 Mar;17(3):962-72
pubmed: 768521
PLoS Pathog. 2013;9(11):e1003729
pubmed: 24244160
Vaccine. 2011 Oct 13;29(44):7733-9
pubmed: 21835220
Trends Biotechnol. 2001 Jun;19(6):231-6
pubmed: 11356285
J Invertebr Pathol. 2011 Jul;107 Suppl:S42-8
pubmed: 21784230
J Sep Sci. 2020 Jun;43(12):2270-2278
pubmed: 32187844
Vaccines (Basel). 2018 May 25;6(2):
pubmed: 29799445
J Gen Virol. 2018 Feb;99(2):265-274
pubmed: 29300162
J Proteome Res. 2011 Aug 5;10(8):3450-9
pubmed: 21688770
Virol J. 2011 Oct 06;8:462
pubmed: 21975161
Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S11-7
pubmed: 18649932
Vaccine. 2019 Nov 8;37(47):7070-7080
pubmed: 31300289
J Sep Sci. 2019 Aug;42(16):2640-2649
pubmed: 31169979
J Sep Sci. 2017 Feb;40(4):979-990
pubmed: 27928907
J Virol. 2017 Feb 28;91(6):
pubmed: 28077638
Expert Rev Vaccines. 2012 Aug;11(8):995-1007
pubmed: 23002980
Expert Rev Vaccines. 2011 Jul;10(7):1063-81
pubmed: 21806400
PLoS One. 2012;7(12):e51559
pubmed: 23236516